SGM 1019

Drug Profile

SGM 1019

Alternative Names: SGM1019

Latest Information Update: 02 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Second Genome
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
  • Mechanism of Action Gastrointestinal microbiome modulators; Inflammasome inhibitors; Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases; Non-alcoholic steatohepatitis

Most Recent Events

  • 02 Aug 2018 SGM-1019 is still in phase I trials for Inflmmatory bowel disease (Second Genome pipeline - August 2018)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease(In volunteers) in USA (PO)
  • 11 Apr 2018 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis presented at the International Liver Congress (ILC-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top